Zauderer Maurice 4
4 · VACCINEX, INC. · Filed Sep 20, 2024
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Zauderer Maurice
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2024-09-18$5.64/sh+38,610$217,606→ 176,748 total(indirect: By Vaccinex (Rochester), L.L.C.) - Exercise/Conversion
Warrant (Right to Buy)
2024-09-18−38,610→ 0 total(indirect: By Vaccinex (Rochester), L.L.C.)Exercise: $5.64From: 2024-03-28Exp: 2029-03-28→ Common Stock (38,610 underlying) - Exercise/Conversion
Common Stock
2024-09-18$5.64/sh+35,715$201,290→ 251,788 total(indirect: By Vaccinex (Rochester), L.L.C.) - Exercise/Conversion
Common Stock
2024-09-18$5.64/sh+9,768$55,052→ 216,073 total(indirect: By Vaccinex (Rochester), L.L.C.) - Exercise/Conversion
Warrant (Right to Buy)
2024-09-18−9,768→ 0 total(indirect: By Vaccinex (Rochester), L.L.C.)Exercise: $5.64From: 2023-11-02Exp: 2028-11-02→ Common Stock (9,768 underlying) - Award
Warrant (Right to Buy)
2024-09-18$0.13/sh+170,475$21,309→ 170,475 total(indirect: By Vaccinex (Rochester), L.L.C.)Exercise: $5.64From: 2024-09-18Exp: 2029-09-18→ Common Stock (170,475 underlying) - Exercise/Conversion
Common Stock
2024-09-18$5.64/sh+29,557$166,583→ 206,305 total(indirect: By Vaccinex (Rochester), L.L.C.) - Exercise/Conversion
Warrant (Right to Buy)
2024-09-18−29,557→ 0 total(indirect: By Vaccinex (Rochester), L.L.C.)Exercise: $5.64From: 2024-02-08Exp: 2029-02-08→ Common Stock (29,557 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2024-09-18−35,715→ 0 total(indirect: By Vaccinex (Rochester), L.L.C.)Exercise: $5.64From: 2023-10-03Exp: 2028-10-03→ Common Stock (35,715 underlying)
Holdings
- 1,011(indirect: By Trust)
Common Stock
- 1,580
Common Stock
- 266
Stock Option (Right to Buy)
Exercise: $92.26Exp: 2028-03-30→ Common Stock (266 underlying) - 12
Stock Option (Right to Buy)
Exercise: $3129.00Exp: 2024-03-31→ Common Stock (12 underlying) - 1,016(indirect: By Trust)
Common Stock
- 12
Stock Option (Right to Buy)
Exercise: $3129.00Exp: 2024-06-30→ Common Stock (12 underlying) - 15
Stock Option (Right to Buy)
Exercise: $1491.00Exp: 2025-12-23→ Common Stock (15 underlying) - 1,877
Stock Option (Right to Buy)
Exercise: $8.21Exp: 2034-03-21→ Common Stock (1,877 underlying) - 135
Stock Option (Right to Buy)
Exercise: $1402.80Exp: 2025-02-24→ Common Stock (135 underlying) - 133
Stock Option (Right to Buy)
Exercise: $270.90Exp: 2032-04-01→ Common Stock (133 underlying) - 66
Stock Option (Right to Buy)
Exercise: $615.30Exp: 2031-04-02→ Common Stock (66 underlying)
Footnotes (10)
- [F1]Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
- [F10]This option vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date, except as otherwise provided in the award notice.
- [F2]Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F3]This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.
- [F4]This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.
- [F5]This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.
- [F6]Exercisable in full as of the date of this report.
- [F7]This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
- [F8]This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
- [F9]This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.